Document is current

Article History

Received: 26 June 2020

Accepted: 25 September 2020

First Online: 28 October 2020

Ethics approval and consent to participate

: Ethics Committee approval and informed consent was provided when required by the ethical regulations of the specific centers.

: All the results presented in this article are anonymized and in aggregate form, and no personally identifiable information was used for this study.

: Yannick Allanore received fees or grants from Actelion, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Curzion, Inventiva, Roche, and Sanofi.Oliver Distler had consultancy relationship and/or has received research funding from AbbVie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd., CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, Medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Target Bio Science, and UCB in the area of potential treatments of scleroderma and its complications. In addition, Oliver Distler has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143).Elise Siegert has received speaker fees/compensation for advisory board meetings from Actelion and Boehringer Ingelheim and a grant from Actelion.László Czirják receives honoraria for consulting services (educational services, scientific articles, participation in advisory boards, clinical trials, other) from AbbVie, Actelion, Boehringer Ingelheim, Lilly, MSD, Novartis, Pfizer, Richter, Roche, and UCB.Patricia E Carreira received fees or grants from Actelion, Boehringer Ingelheim, Emmerald Health Pharmaceuticals, Sanofi, AbbVie, Bristol Myers Squibb, and Mitsubishi Tanabe Pharma.Eric Hachulla has no conflicts of interest to declare.Elisabetta Zanatta had consultancy relationship and/or received fees from Actelion and GSK.Mengtao Li declares no conflict of interest.Paolo Airò has received consultancy and/or travel expenses from Bristol Myers Squibb, CSL Behring, Janssen, Novartis, Pfizer, Roche, and SOBI.Fabian A Mendoza had a consultancy relationship with AbbVie, Genentech, and Gilead.Edoardo Rosato has received research funding from Actelion.Sylvie Bozzi, Augustin Terlinden, Caroline Amand, and Christina Soubrane are employees of Sanofi R&D, France.Doerte Huscher has received traveling expenses from Actelion Pharmaceuticals, Boehringer Ingelheim, and Shire International GmbH.